# Mustafa Özgüroğlu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mustafa-ozguroglu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,752 |
| Field | Lung Cancer Research Studies |
| h-index | 61 |
| i10-index | 182 |
| Last Known Institution | Istanbul University-Cerrahpaşa |
| OpenAlex ID | https://openalex.org/A5023874099 |
| ORCID iD | https://orcid.org/0000-0002-8417-8628 |
| Works | 548 |

## Researcher papers

Showing 12 of 14.

- [Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer](https://scholariq.org/papers/durvalumab-after-chemoradiotherapy-in-stage-iii-non-small-cell-lung-cancer/)
- [Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial](https://scholariq.org/papers/prednisone-plus-cabazitaxel-or-mitoxantrone-for-metastatic-castration-resistant/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/abiraterone-plus-prednisone-in-metastatic-castration-sensitive-prostate-cancer/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC](https://scholariq.org/papers/atezolizumab-for-first-line-treatment-of-pd-l1-selected-patients-with-nsclc/)
- [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://scholariq.org/papers/apalutamide-for-metastatic-castration-sensitive-prostate-cancer/)
- [Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/abiraterone-acetate-plus-prednisone-in-patients-with-newly-diagnosed-high-risk/)
- [Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/survival-with-olaparib-in-metastatic-castration-resistant-prostate-cancer/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-alone-or-combined-with-chemotherapy-versus-chemotherapy-as-first/)
- [Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study](https://scholariq.org/papers/apalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Researcher university

- [Istanbul University-Cerrahpaşa](https://scholariq.org/institutions/istanbul-university-cerrahpasa/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.